Targocid 400mg Injection

The antibiotic Targocid 400mg Injection contains teicoplanin. Many bacterial infections, particularly those brought on by Gram-positive bacteria, are treated with it. When it comes to methicillin-resistant Staphylococcus aureus (MRSA) and other antibiotic-resistant infections, it works especially well.

Uses of Targocid 400mg Injection:

• Septicemia (blood infections)
• Endocarditis (heart valve infection)
• Bone and joint infections
• Respiratory tract infections
• Skin and soft tissue infections
• Urinary tract infections

How does Targocid 400mg Injection work?

Teicoplanin acts by inhibiting synthesis of bacterial cell walls. It kills the bacterium by binding to the D-alanyl-D-alanine residues of peptidoglycan in the bacterial cell wall, thus inhibiting cross-linking. This approach is particularly effective with Gram-positive bacteria.

How to Use & Dosage?

Intravenous The dosage is dependent on the type and severity of infection, renal function and age of the patient. It is given every 8 hours in general.

Possible Side Effects:

• Nausea
• Vomiting
• Diarrhea
• Rash
• Headache
• Allergic reactions
• Seizures
• Thrombocytosis

Safety Advise:

Kidneys

Teicoplanin is mainly excreted by the kidneys, therefore the dose has to be adjusted in patients with renal impairment. Be sure to speak with your health care provider.

Liver

Meropenem can increase liver enzymes and therefore liver function tests should be monitored during prolonged therapy, especially in patients with liver disease. Talk to your doctor.

Pregnancy

PregnancyThe use of Teicoplanin during pregnancy has not been fully established. Use only when clearly needed and under medical supervision. Discuss with your healthcare provider.

Breast-Feeding

Use with caution during breast-feeding. The drug can pass into breast milk. Please consult your health care provider.

Driving

Injection side effects may affect your ability to drive. Talk with your health care provider.

Storage Instructions:

Store in a cool & dry place away from sunlight. Store the vials at room temperature before reconstituting. On reconstitution, the solution should be used within the time specified by the manufacturer to ensure stability and effectiveness.

References:

1. Wilson AP. Clinical pharmacokinetics of teicoplanin. Clinical pharmacokinetics. 2000 Sep;39:167-83.
2. Shea KW, Cunha BA. Teicoplanin. The Medical clinics of North America. 1995 Jul 1;79(4):833-44.
3. Davey PG, Williams AH. A review of the safety profile of teicoplanin. Journal of Antimicrobial Chemotherapy. 1991 Jan 1;27(suppl_B):69-73.
4. Campoli-Richards DM, Brogden RN, Faulds D. Teicoplanin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs. 1990 Sep;40(3):449-86.
5. Parenti F, Schito GC, Courvalin P. Teicoplanin chemistry and microbiology. Journal of Chemotherapy. 2000 Nov 1;12(sup5):5-14.

Disclaimer:

IHS Enterprises’s primary objective is to guarantee the accuracy, reliability, and specialist review of the information it provides to customers. The contents and information provided on this website are for informational purposes only. They should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician for guidance and any questions you may have about any condition or medication. If you do read anything from IHS Enterprises, please do not discount or delay in seeking competent medical advice. We want to enhance the doctor-patient relationship, not substitute it.

Manufacturer details:

Marketer details
Name: Sanofi India Ltd
Address: Sanofi House, CTS No.117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400072
Country of origin: Italy